SCHEMBL4338643

SCHEMBL4338643

CCN(CCC#N)C(=O)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 3/20 0.68
ALDH1A1 P00352 7/20 0.58
HPGD P15428 4/20 0.58
L3MBTL1 Q9Y468 3/20 0.58
NPC1 O15118 1/20 0.58
MAPT P10636 2/20 0.54
GAA P10253 2/20 0.54
POLB P06746 2/20 0.50
LIMK1 P53667 1/20 0.50
LIMK2 P53671 1/20 0.50
CTSL P07711 1/20 0.49
CTSS P25774 1/20 0.49
TP53 P04637 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11531217 0.90 ALDH1A1 (0.70) MLYCDALDH1A1HPGDL3MBTL1NPC1
SCHEMBL11212992 0.84 HPGD (0.72) ALDH1A1HPGDL3MBTL1MAPTGAA
SCHEMBL14339827 0.82 HPGD (0.53) MLYCDALDH1A1HPGDL3MBTL1MAPT
SCHEMBL5166929 0.81 HPGD (0.68) MLYCDALDH1A1HPGDL3MBTL1MAPT
SCHEMBL2614245 0.81 HPGD (0.71) ALDH1A1HPGDL3MBTL1MAPTGAA
SCHEMBL72112 0.80 HPGD (0.85) MLYCDALDH1A1HPGDL3MBTL1MAPT
SCHEMBL4351971 0.80 ALDH1A1 (0.52) MLYCDALDH1A1L3MBTL1NPC1MAPT
SCHEMBL11213668 0.80 HPGD (0.69) ALDH1A1HPGDL3MBTL1NPC1MAPT
SCHEMBL1003828 0.80 HPGD (0.66) ALDH1A1HPGDL3MBTL1MAPTGAA
Hydrochloric Acid SCHEMBL6612619 0.79 HPGD (0.81) MLYCDALDH1A1HPGDL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2056829-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER Exelixis, Inc. (US) 2009-05-13 EP claimed
WO-2008021389-A2 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS, INC. (US) 2008-02-21 WO claimed